Summary
Renal cell carcinomas, which originate within the renal cortex, constitute 80–85% of primary renal neoplasms. Patients can present with a range of symptoms due to the tumor itself (e.g., mass, pain), invasion of the urinary tract (e.g., hematuria), paraneoplastic syndromes, or the presence of metastases. Renal cell cancer is more frequently being diagnosed incidentally as a consequence of increased use of imaging procedures for other reasons. Surgery is curative in the majority of patients without metastatic disease and is therefore the preferred treatment for patients with stages I, II, and III disease. The five-year survival following the treatment correlates well with the anatomic extent of disease. Systemic therapy with molecularly targeted therapy or immunotherapy is the primary approache for patients with unresectable or recurrent disease.
Zusammenfassung
Das kortikale Nierenzellkarzinom trägt 80–85 % zu den bekannten Neoplasien der Niere bei. Die Symptomatik des Patienten ist entweder auf den Tumor selbst (z. B. Schmerz), Invasion des Harntraktes (z. B. Hämaturie), paraneoplastische Syndromen oder Metastasen zurückzuführen. Am häufigsten wird das Nierenzellkarzinom heute als Zufallsbefund eines bildgebenden Verfahrens im Initialstadium detektiert. Die chirurgische Therapie gilt als bevorzugte Behandlung im metastasenfreien Stadium I, II und III. Das 5-Jahresüberleben korreliert eng mit der anatomischen Ausdehnung des Tumors. Systemische Substanzen, wie Targeted- oder Immuntherapie kommen in fortgeschrittenen Stadien zum Einsatz.
Similar content being viewed by others
Literatur
Auszug aus: Österreichisches Krebsregister, Statistik Austria, Stand: 11.9.2007
Jemal A, Siegel R, Ward E. Cancer statistic. CA Cancer J Clin, 57: 43–66, 2007
Patel PH, Chaganti RS, Motzer R. Targeted therapy for metastatic renal cell carcinoma. Br J Cancer, 94: 614–619, 2006
Hunt JD, van der Hel OL, McMillan GP. Renal cell carcinoma in relation to cigarette smoking: meta-analysis of 24 studies. Int J Cancer, 114: 101–108, 2005
Maclure M. Asbestos and renal adenocarcinoma: a case-control study. Environ Res, 42: 353–361, 1987
McLaughlin JK, Blot WJ, Mehl ES. Petroleum-related employment and renal cell cancer. J Occup Med, 27: 672–674, 1985
Chow WH, Gridley G, Fraumeni JF Jr, Jarvholm B. Obesity, hypertension, and the risk of kidney cancer in men. N Engl J Med, 343: 1305–1311, 2000
Truong LD, Krishnan B, Cao JT. Renal neoplasm in acquired cystic kidney disease. Am J Kidney Dis, 26: 1–12, 1995
Thoenes W, Storkel S, Rumpelt HJ. Histopathology and classification of renal cell tumors (adenomas, oncocytomas and carcinomas): the basic cytological and histopathological elements and their use for diagnostics. Pathol Res Pract, 1181: 125–143, 1986
Storkel S, van den Berg E. Morphologic classification of renal Cancer. World J Urol, 13: 153–158, 1995
Patard JJ, Leray E, Rioux-Leclercq N. Prognostic value of histologic subtypes in renal cell carcinoma: a multicenter experience. J Clin Oncol, 23: 2763–2771, 2005
Presti JC Jr, Rao PH, Chen Q. Histopathological, cytogenetic, and molecular characterization of renal cortical tumors. Cancer Res, 51: 1544–1552, 1991
Weiss LM, Gelb AB, Medeiros LJ. Adult renal epithelial neoplasms. Am J Clin Pathol, 103: 624–635, 1995
Garnick MB. Primary neoplasms of the kidney. In: Brady HR, Wilcox CS (eds) Therapy in nephrology and hypertension: a companion to Brenner and Rector's the Kidney. Saunders WB, Philadelphia, 1998
Skinner DG, Colvin RB, Vermillion CD. Diagnosis and management of renal cell carcinoma. A clinical and pathologic study of 309 cases. Cancer, 28: 1165–1177, 1971
Chisholm GD, Roy RR. The systemic effects of malignant renal tumours. Br J Urol, 43: 687–700, 1971
Gold PJ, Fefer A, Thompson JA. Paraneoplastic manifestations of renal cell carcinoma. Semin Urol Oncol, 14: 216–222, 1996
Johnson CD, Dunnick NR, Cohan RH, Illescas FF. Renal adenocarcinoma: CT staging of 100 tumors. AJR Am J Roentgenol, 148: 59–63, 1987
McDougal WS, Garnick MB. Clinical signs and symptoms of kidney cancer. In: Vogelzang NJ, Scardino PT, Shiple WU Comprehensive textbook of genitourinary oncology. Williams & Wilkins, Baltimore, 1996
Gilbert SM, Murphy AM, Katz AE. Reevaluation of TNM staging of renal cortical tumors: recurrence and survival for T1N0M0 and T3aN0M0 tumors are equivalent. Urology, 68: 287–291, 2006
Motzer RJ, Russo P. Systemic therapy for renal cell carcinoma. J Urol, 163: 408–417, 2000
Permpongkosol S, Chan DY, Link RE, Jarret TW, Kavoussi LR. Laparoscopic radical nephrectomy: long-term ourtcomes. J Endourol, 19: 628–633, 2005
Novik AC. Laparoscopic and partial nephrectomy. Clin Cancer Res, 15: 6322–6327, 2004
Lam JS, Shvarts O, Leppert JT. Postoperative surveillance protocol for patients with localized and locally advanced renal cell carcinoma based on a validated prognostic nomogram and risk group stratification system. J Urol, 174: 466–472, 2005
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Ferber, W., Schramek, P. Die urologische Therapie des Nierenzellkarzinoms. Wien Med Wochenschr 158, 307–311 (2008). https://doi.org/10.1007/s10354-008-0556-5
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/s10354-008-0556-5